News Archive

to receive news alerts

2012  
2011  
2010  
2009  
2008  
2007  
2006  
Thu, 01/26/2012

Healthpoint Biotherapeutics today advised that the Centers for Medicare and Medicaid Services (CMS) has eliminated the physician 90-day global surgical period for the application of all skin and dermal substitutes, including OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix. Additionally, the American Medical Association has created eight new CPT® codes that apply to brands in the skin substitute category, resulting in the same Medicare allowable rates for the application of all covered brands of skin and dermal substitutes.

Thu, 01/05/2012

Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 9th, at 9:30 am (PST) at the Westin St. Francis Hotel in San Francisco, CA.